AAPL   394.51 (+2.82%)
MSFT   214.37 (+0.33%)
FB   246.97 (+0.78%)
GOOGL   1,559.78 (+1.35%)
AMZN   3,285.07 (+2.66%)
BABA   258.10 (-1.11%)
MU   50.90 (+0.39%)
GE   6.78 (+1.35%)
TSLA   1,673.09 (+8.32%)
AMD   56.52 (+1.13%)
T   29.87 (-0.86%)
ACB   12.54 (+4.33%)
F   6.20 (+1.64%)
GILD   77.81 (+1.95%)
NFLX   562.11 (+2.44%)
BA   182.68 (+2.38%)
AAPL   394.51 (+2.82%)
MSFT   214.37 (+0.33%)
FB   246.97 (+0.78%)
GOOGL   1,559.78 (+1.35%)
AMZN   3,285.07 (+2.66%)
BABA   258.10 (-1.11%)
MU   50.90 (+0.39%)
GE   6.78 (+1.35%)
TSLA   1,673.09 (+8.32%)
AMD   56.52 (+1.13%)
T   29.87 (-0.86%)
ACB   12.54 (+4.33%)
F   6.20 (+1.64%)
GILD   77.81 (+1.95%)
NFLX   562.11 (+2.44%)
BA   182.68 (+2.38%)
AAPL   394.51 (+2.82%)
MSFT   214.37 (+0.33%)
FB   246.97 (+0.78%)
GOOGL   1,559.78 (+1.35%)
AMZN   3,285.07 (+2.66%)
BABA   258.10 (-1.11%)
MU   50.90 (+0.39%)
GE   6.78 (+1.35%)
TSLA   1,673.09 (+8.32%)
AMD   56.52 (+1.13%)
T   29.87 (-0.86%)
ACB   12.54 (+4.33%)
F   6.20 (+1.64%)
GILD   77.81 (+1.95%)
NFLX   562.11 (+2.44%)
BA   182.68 (+2.38%)
AAPL   394.51 (+2.82%)
MSFT   214.37 (+0.33%)
FB   246.97 (+0.78%)
GOOGL   1,559.78 (+1.35%)
AMZN   3,285.07 (+2.66%)
BABA   258.10 (-1.11%)
MU   50.90 (+0.39%)
GE   6.78 (+1.35%)
TSLA   1,673.09 (+8.32%)
AMD   56.52 (+1.13%)
T   29.87 (-0.86%)
ACB   12.54 (+4.33%)
F   6.20 (+1.64%)
GILD   77.81 (+1.95%)
NFLX   562.11 (+2.44%)
BA   182.68 (+2.38%)
Log in

NASDAQ:CLSDClearside Biomedical Stock Price, Forecast & News

$1.73
-0.01 (-0.57 %)
(As of 07/13/2020 01:44 PM ET)
Add
Compare
Today's Range
$1.71
Now: $1.73
$1.75
50-Day Range
$1.77
MA: $1.98
$2.22
52-Week Range
$0.56
Now: $1.73
$4.13
Volume3,012 shs
Average Volume277,299 shs
Market Capitalization$77.63 million
P/E RatioN/A
Dividend YieldN/A
Beta1.06
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Read More
Clearside Biomedical logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.32 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLSD
CUSIPN/A
Phone678-270-3631

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.17 million
Book Value$0.25 per share

Profitability

Net Income$-30,770,000.00
Net Margins-293.61%

Miscellaneous

Employees50
Market Cap$77.63 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive CLSD News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter.

Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions

How has Clearside Biomedical's stock been impacted by COVID-19 (Coronavirus)?

Clearside Biomedical's stock was trading at $2.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CLSD stock has decreased by 33.2% and is now trading at $1.73. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Clearside Biomedical?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Clearside Biomedical.

When is Clearside Biomedical's next earnings date?

Clearside Biomedical is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Clearside Biomedical.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical Inc (NASDAQ:CLSD) announced its earnings results on Friday, May, 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. The business earned $4.10 million during the quarter, compared to the consensus estimate of $4 million. Clearside Biomedical had a negative return on equity of 165.19% and a negative net margin of 293.61%. View Clearside Biomedical's earnings history.

What price target have analysts set for CLSD?

6 analysts have issued 1-year price targets for Clearside Biomedical's stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate Clearside Biomedical's stock price to reach $5.75 in the next year. This suggests a possible upside of 232.4% from the stock's current price. View analysts' price targets for Clearside Biomedical.

Has Clearside Biomedical been receiving favorable news coverage?

News coverage about CLSD stock has been trending very negative on Monday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Clearside Biomedical earned a news impact score of -3.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Clearside Biomedical.

Who are some of Clearside Biomedical's key competitors?

What other stocks do shareholders of Clearside Biomedical own?

Who are Clearside Biomedical's key executives?

Clearside Biomedical's management team includes the following people:
  • Dr. George M. Lasezkay Pharma.D., J.D., Interim CEO & Director (Age 67)
  • Mr. Charles A. Deignan, Chief Financial Officer (Age 55)
  • Mr. Stephen C. Kilmer, Investor Relations Officer (Age 53)
  • Mr. Leslie B. Zacks, Gen. Counsel, Chief Compliance Officer & Sec. (Age 50)
  • Mr. Rick McElheny, VP of Corp. Devel.

When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

How do I buy shares of Clearside Biomedical?

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Clearside Biomedical's stock price today?

One share of CLSD stock can currently be purchased for approximately $1.73.

How big of a company is Clearside Biomedical?

Clearside Biomedical has a market capitalization of $77.63 million and generates $2.17 million in revenue each year. The company earns $-30,770,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Clearside Biomedical employs 50 workers across the globe.

What is Clearside Biomedical's official website?

The official website for Clearside Biomedical is www.clearsidebio.com.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.